Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pediatrics, Perinatology and Child Health
Reference92 articles.
1. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–28.
2. O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase Inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(02):ii111–5.
3. chmp-post-authorisation-summary-opinion-olumiant-x-35-g_en.pdf [Internet]. [cited 2023 Jul 25]. https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-olumiant-x-35-g_en.pdf. Accessed 2 Sept 2022.
4. Johnston JA, Kawamura M, Kirken RA, Chen YQ, Blake TB, Shibuya K, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 1994;370(6485):151–3.
5. Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25.